Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program
Alzheimer's & Dementia · 2025
DOI: 10.1002/alz.70245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Valentina Ghisays und 14 weiteren Autor:innen. Beteiligte Einrichtung: Banner Alzheimer's Institute, Phoenix, Arizona, USA. Hauptthemen laut MEDLINE: Apolipoprotein E4, Dementia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Driver Project Subaward, NIA NIH HHS, National Institutes of Health (NIH).
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Longitudinal electronic health records (EHRs), “dementia” diagnostic codes, and genetic data from All of Us were used to see if there is a higher risk of dementia and an attenuated impact of apolipoprotein ε4 (APOE4) on Alzheimer's disease (AD) risk in Black and Hispanic/Latino groups. METHODS Participants included 9,784 Hispanic/Latinos, 14,937 Non‐Hispanic Blacks (NHB), and 60,388 Non‐Hispanic Whites (NHWs) ≥age 60 without an initial dementia diagnosis. RESULTS There was a significantly higher risk of developing a dementia diagnosis in Hispanic/Latino and NHB participants than NHW participants and comparably increased dementia hazard ratios in the Hispanic/Latino, NHB, and NHW APOE4 carriers than non‐carriers (hazard ratio [HR] [95% confidence interval {CI}] 1.54 [1.25–1.91], 1.25 [1.00–1.57], and 1.55 [1.40–1.72]). DISCUSSION Compared to NHW individuals, Hispanic/Latino and NHB individuals are at higher risk of developing a “dementia diagnosis” and comparably higher risk in APOE4 carriers than non‐carriers. Plasma AD biomarkers could clarify the proportion of dementia cases with and without AD and the impact of APOE4 on AD in these groups. Highlights Hispanic/Latino and non‐Hispanic Black individuals have a higher risk of all‐cause dementia. The impact of apolipoprotein ε4 (APOE4) on dementia risk was similar in the studied ethnoracial groups. Plasma biomarkers could inform the risk of Alzheimer's disease (AD) and impact of APOE4 in these groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Banner Alzheimer's Institute, Phoenix, Arizona, USA.
- Department of Pharmacy Practice and Science, R. Ken Coit College of Pharmacy, University of Arizona, Tucson, Arizona, USA.
- Early Detection and Prevention Division, Translational Genomics Research Institute, Phoenix, Arizona, USA.
- Department of Cell Biology and Physiology, University of Kansas Medical Center, Kansas City, Kansas, USA.
Förderung
- Driver Project Subaward
- NIA NIH HHS
- National Institutes of Health (NIH)
- NIH, Office of the Director
- State of Arizona DHS via Arizona Alzheimer's Research Consortium (AARC)
- NHLBI NIH HHS
- ODCDC CDC HHS
- National Institute of Health and Arizona ADRC
Zitieren
APA
Ghisays, V., Khajouei, E., Piras, I. S., Malek-Ahmadi, M. H., Protas, H. D., Goradia, D. D., Chen, Y., Naymik, M., Saner, D., Veatch, O. J., Mansel, C. O., Su, Y., Huentelman, M. J., Karnes, J. H., & Reiman, E. M. (2025). Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70245
Vancouver
Ghisays V, Khajouei E, Piras IS, Malek-Ahmadi MH, Protas HD, Goradia DD, et al. Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70245
BibTeX
@article{Ghisays2025,
author = {Ghisays, Valentina and Khajouei, Ehsan and Piras, Ignazio S and Malek-Ahmadi, Michael H and Protas, Hillary D and Goradia, Dhruman D and Chen, Yinghua and Naymik, Marcus and Saner, Donald and Veatch, Olivia J and Mansel, Clayton O and Su, Yi and Huentelman, Matthew J and Karnes, Jason H and Reiman, Eric M},
title = {Impact of APOE4‐related dementia risk in underrepresented groups from the All of Us research program},
journal = {Alzheimer's & Dementia},
year = {2025},
doi = {10.1002/alz.70245}
}
EUVIMED